In a clinical trial conducted at Duke University, eighteen patients with recurrent malignant brain tumors had the 211At-labeled anti-tenascin MAb 81C6 administered locally into the surgically created resection cavities [19]. The gene discussed is TNC; the disease is brain cancer.